Novotech, the award-winning Asia-Pacific CRO, with 23 years of experience in the region, has further strengthened its presence in the Asia-Pacific with a Partnership with the Skin Research Institute of Singapore (SRIS).

Novotech now has over 20 significant Partnerships with some of the leading medical institutions in the region. The Partnership Program is strategically designed to bring unparalleled access to quality investigators, KOLs, and up to 4 million patients for its international biotech clients.

SRIS was established as a collaboration between the Agency for Science Technology and Research (A*STAR), National Healthcare Group (NHG) and Nanyang Technological University (NTU).

It was launched in September 2013 and harnesses expertise of scientists, clinicians and engineers to foster and conduct high impact, inter-disciplinary skin research that would translate into improved health outcomes and quality of life.

With this partnership, SRIS and Novotech formalize their long-standing working relationship. This partnership agreement enables both parties to have a closer collaboration to ensure high priority start-up of new projects, and in the areas of clinical trial promotion, business development, networking opportunities, clinical operations, training, and feasibility assessments. The two groups will be working together to promote the combined capabilities in Skin research clinical trials.

Novotech CEO Dr John Moller said the Partnership with SRIS will support the increasing demand from biotech clients for skin disorder studies in the Asia-Pacific region.

“Novotech is well established in the region with offices in 11 countries and more than 600 staff,” he said. “We use the very latest in Oracle and Medidata technology, so seamlessly connect across all its offices and with global clinical partners.”